Protez Pharmaceuticals protez.com


Public lists: Pharma Startups (4733)

Protez Pharmaceuticals entered a 20-site Phase II human clinical trial in 2008 with its lead compound, PZ-601, a antibiotic candidate focused on drug resistance in difficult to treat infections.

Protez Pharmaceuticals entered a 20-site Phase II human clinical trial in 2008 with its lead compound, PZ-601, a antibiotic candidate focused on drug resistance in difficult to treat infections.

Company (Acquired)

Phone: 610-695-0200

Fax:

30 Spring Mill Drive

Malvern, 19355
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Protez Pharmaceuticals $23.7M Jul 21, 2008
KAI Pharmaceuticals $63M Apr 11, 2012
Affinium Pharmaceuticals $44.9M Sep 12, 2013
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Protez Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 13 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)